Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B

BACKGROUND/AIMS: Entecavir (ETV) can suppress chronic hepatitis B (CHB) virus replication as a standard of treatment drugs. For the treatment of CHB, affordable generic drugs may be more widely used in developing and undeveloped countries. However, there is little real-world data regarding the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Po-Ke, Su, Pei-Yuan, Wu, Chia-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088125/
https://www.ncbi.nlm.nih.gov/pubmed/35538425
http://dx.doi.org/10.1186/s12876-022-02317-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088125/
https://www.ncbi.nlm.nih.gov/pubmed/35538425
http://dx.doi.org/10.1186/s12876-022-02317-7

Ejemplares similares